Nanomaterials in Alzheimer’s disease treatment: a comprehensive review
Author(s) -
Maryam Faiyaz,
Mohd Azhardin Ganayee,
Salman Akhtar,
Saravanan Krishnan,
Bableen Flora,
Deeksha Dogra,
Niraj Kumar Jha,
Dinesh Kumar Chellappan,
Poonam Negi,
Kamal Dua,
Kavindra Kumar Kesari,
Piyush Kumar Gupta
Publication year - 2021
Publication title -
frontiers in bioscience-landmark
Language(s) - Uncategorized
Resource type - Journals
eISSN - 2768-6701
pISSN - 2768-6698
DOI - 10.52586/4992
Subject(s) - disease , dementia , medicine , neuroscience , alzheimer's disease , inflammation , psychology , immunology , pathology
Alzheimer's, a progressive neurodegenerative disease affects brain and neurons through enormous reduction in nerve cell regenerative capacity. Dementia and impairment of cognitive functions are more prevalent in Alzheimer's disease (AD) patients in both industrialized and non-industrialized countries. Various factors play significant role in molecular cascades that leads to neuronal inflammation, dementia and thereby AD progression. Current medications are symptomatic that alleviates pain while lack in absolute cure, urging researchers to explore targets and therapeutics. Interestingly, nanomedicines developed due to the onset of nanotechnology, are being extensively investigated for the treatment of AD. This review presents the advancement in nanotherapeutic strategies, involving the emergence of nanomaterials that offers advantage to pass through the blood-brain barrier and acts as a therapeutic modality against AD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom